Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

INDUSTRY 4OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2

Interventions

Carboplatin 28Paclitaxel 21Cisplatin 9Topotecan 8Docetaxel 7Taxes 6Oxaliplatin 5Gemcitabine 5Chemotherapy, Adjuvant 5Bevacizumab 5aldesleukin 4Interleukin-12 Subunit p35 4Erlotinib Hydrochloride 4Drug Therapy 4Interleukin-12 3Immunohistochemistry 3Imatinib Mesylate 3Gene Expression Profiling 3Flow Cytometry 3Filgrastim 3Cyclophosphamide 3Amplified Fragment Length Polymorphism Analysis 3trioctyl phosphine oxide 2temsirolimus 2sargramostim 2oregovomab 2ixabepilone 2irofulven 2cediranib 2carboxyamido-triazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Carcinoma, Ovarian Epithelial × oregovomab × Clear all
NCT00003634 2013-11-06

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

National Cancer Institute (NCI)

Phase 2 Unknown
400 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00004064 2013-11-06

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
102 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡